NCT07286006
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatmentImmunovant Sciences GmbH
~372 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:IMVT-1402
At a glance
Recruiting sites
0 of 105 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402
Measured over At Week 52
Conditions
Where it's being run
105 sites across 36 statesTexas16
Florida12
California7
North Carolina6
Bulgaria6
New York5
Georgia4
Tennessee4
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.
Exclusion
Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.
What this trial measures
- Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402At Week 52